RHYTHM PHARMACEUTICALS INC. - COMMON STOCK

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients as Young as 2 Years Old

20 ديسمبر 2024 14:15:00 بحسب Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces ▼ IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency to include Children as Young as 2 Years Old

03 ديسمبر 2024 06:00:00 بحسب Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide

18 نوفمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & Endocrinology

13 نوفمبر 2024 18:30:00 بحسب Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

13 نوفمبر 2024 16:01:00 بحسب Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

06 نوفمبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Update

05 نوفمبر 2024 16:01:00 بحسب Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Five New Data Presentations at ObesityWeek® 2024

04 نوفمبر 2024 16:01:00 بحسب Nasdaq GlobeNewswire

Rhythm Pharmaceuticals and Axovia Therapeutics Announce Joint Research Collaboration in Bardet-Biedl Syndrome

24 أكتوبر 2024 06:00:00 بحسب Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 5, 2024

23 أكتوبر 2024 08:00:01 بحسب Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

08 أكتوبر 2024 16:01:00 بحسب Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

16 سبتمبر 2024 16:01:00 بحسب Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for IMCIVREE® (setmelanotide) in Patients as Young as 2 years old

26 أغسطس 2024 08:02:00 بحسب Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Present at Wells Fargo Healthcare Conference in September

26 أغسطس 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

13 أغسطس 2024 16:01:00 بحسب Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Update

06 أغسطس 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces European Commission Expands ▼IMCIVREE® (setmelanotide) Marketing Authorization to include Children as Young as 2 Years Old

31 يوليو 2024 09:10:21 بحسب Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces First Patients Dosed in Phase 2 Trial Evaluating Oral MC4R Agonist LB54640 in Hypothalamic Obesity

23 يوليو 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Report Second Quarter 2024 Financial Results on Tuesday, August 6, 2024

23 يوليو 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

11 يوليو 2024 16:01:00 بحسب Nasdaq GlobeNewswire